Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
| Indexado |
|
||||
| DOI | 10.1093/ALCALC/AGAC015 | ||||
| Año | 2022 | ||||
| Tipo | artículo de investigación |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
Aims Readmission is frequent among patients with cirrhosis and is a complex multifactorial process. To examine the association of alcohol use disorder (AUD) and risk of readmission in patients with alcohol-associated cirrhosis. Methods and Results National Readmission Dataset (2016-2017) was used to extract a retrospective cohort of 53,348 patients with primary or secondary discharge diagnosis code of alcohol-associated cirrhosis with their first admission (26,674 patients with vs. propensity matched 26,674 without a primary or secondary discharge diagnosis code of AUD). Readmission within 30-day was lower (43.9 vs. 48%, P < 0.001) among patients identified to have AUD at the time of discharge. In a conditional logistic regression model, a diagnosis of AUD was associated with 15% reduced odds of 30-day readmission, 0.85 (0.83-0.88). Furthermore, the reason for readmission among patients identified vs. not identified to have AUD was less likely to be liver disease complication. The findings remained similar in a matched cohort of patients where the AUD diagnosis at discharge was listed as one of the secondary diagnoses only. Conclusion Although, our study findings suggest that identification of AUD at the time of discharge among patients hospitalized for alcohol-associated cirrhosis reduces the risk of 30-day readmission, unavailable information on patient counseling, referral for mental health specialist and treatment received for AUD limit the causality assessment. Future studies are needed overcoming the inherent limitations of the database to establish the role of identification and treatment of AUD in reducing readmission and liver decompensation in patients with alcohol-associated cirrhosis.
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | Singal, Ashwani K. | - |
Univ South Dakota - Estados Unidos
Avera Transplant Inst - Estados Unidos Mckennan Univ Hosp - Estados Unidos University of South Dakota - Estados Unidos Avera McKennan Hospital and University Health Center - Estados Unidos Sanford School of Medicine - Estados Unidos |
| 2 | DiMartini, Andrea | Mujer |
Univ Pittsburgh - Estados Unidos
University of Pittsburgh Medical Center - Estados Unidos University of Pittsburgh School of Medicine - Estados Unidos |
| 3 | Leggio, Lorenzo | Hombre |
Natl Inst Hlth - Estados Unidos
Johns Hopkins Univ - Estados Unidos Georgetown Univ - Estados Unidos National Institute on Alcohol Abuse and Alcoholism (NIAAA) - Estados Unidos National Institutes of Health (NIH) - Estados Unidos Center for Alcohol and Addiction Studies - Estados Unidos Johns Hopkins School of Medicine - Estados Unidos Georgetown University Medical Center - Estados Unidos National Institute on Drug Abuse (NIDA) - Estados Unidos Johns Hopkins University School of Medicine - Estados Unidos |
| 4 | Arab, Juanpablo | Hombre |
Brown Univ - Estados Unidos
Pontificia Universidad Católica de Chile - Chile Escuela de Medicina - Chile |
| 5 | Kuo, Yong-Fang | Hombre |
Univ Texas Med Branch - Estados Unidos
UT Medical Branch at Galveston - Estados Unidos The University of Texas Medical Branch at Galveston - Estados Unidos |
| 6 | Shah, Vijay H. | Hombre |
Mayo Clin - Estados Unidos
Mayo Clinic - Estados Unidos |
| Fuente |
|---|
| National Institute on Drug Abuse |
| Chilean government through the Fondo Nacional de Desarrollo Cientifico y Tecnologico |
| National Institute on Alcohol Abuse and Alcoholism |
| National Institute on Drug Abuse (NIDA) |
| National Institute On Alcohol Abuse And Alcoholism (NIAAA) |
| Agencia Nacional de Investigacion y Desarrollo, ANID |
| Agradecimiento |
|---|
| L.L. is a US federal employee at the NIH and he is jointly funded by the intramural research programs of the National Institute on Drug Abuse (NIDA) and the National Institute on Alcohol Abuse and Alcoholism (NIAAA; ZIA-DA000635 and ZIAAA000218). This article was partially supported by the Chilean government through the Fondo Nacional de Desarrollo Cientifico y Tecnologico (FONDECYT 1200227 to J. P.A.) and the Agencia Nacional de Investigacion y desarrollo, ANID through ANID ACE 210009 grant (to J.P.A.). |